DK3541833T3 - TGFß signalkonverter - Google Patents
TGFß signalkonverter Download PDFInfo
- Publication number
- DK3541833T3 DK3541833T3 DK17872043.9T DK17872043T DK3541833T3 DK 3541833 T3 DK3541833 T3 DK 3541833T3 DK 17872043 T DK17872043 T DK 17872043T DK 3541833 T3 DK3541833 T3 DK 3541833T3
- Authority
- DK
- Denmark
- Prior art keywords
- tgfß
- signal converter
- converter
- signal
- tgfß signal
- Prior art date
Links
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423565P | 2016-11-17 | 2016-11-17 | |
US201762467496P | 2017-03-06 | 2017-03-06 | |
PCT/US2017/062358 WO2018094244A1 (en) | 2016-11-17 | 2017-11-17 | TGFβ SIGNAL CONVERTOR |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3541833T3 true DK3541833T3 (da) | 2024-04-02 |
Family
ID=62145775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17872043.9T DK3541833T3 (da) | 2016-11-17 | 2017-11-17 | TGFß signalkonverter |
Country Status (13)
Country | Link |
---|---|
US (2) | US11654158B2 (da) |
EP (2) | EP3541833B1 (da) |
JP (2) | JP7263235B2 (da) |
KR (2) | KR20240046620A (da) |
CN (2) | CN117720665A (da) |
AU (3) | AU2017362484B2 (da) |
BR (1) | BR112019009904A2 (da) |
CA (1) | CA3043888A1 (da) |
DK (1) | DK3541833T3 (da) |
IL (2) | IL266628B2 (da) |
MA (1) | MA46862A (da) |
MX (1) | MX2019005724A (da) |
WO (1) | WO2018094244A1 (da) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US20180147271A1 (en) * | 2015-05-18 | 2018-05-31 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CN117720665A (zh) | 2016-11-17 | 2024-03-19 | 2赛文缇生物公司 | TGFβ信号转换器 |
WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
CA3084551A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
MX2020009051A (es) | 2018-03-02 | 2020-12-03 | Allogene Therapeutics Inc | Receptores de citocina quimericos inducibles. |
CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
EP3848387A4 (en) * | 2018-09-05 | 2022-06-22 | Kong, Seogkyoung | CHIMERIC ANTIGEN RECEPTOR FOR SOLID TUMOR AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR |
EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
CN114375301A (zh) * | 2019-05-08 | 2022-04-19 | 基因医疗免疫疗法有限责任公司 | 工程改造的t细胞 |
WO2021041806A1 (en) * | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
WO2021074161A1 (en) * | 2019-10-15 | 2021-04-22 | ETH Zürich | Artificial transmembrane proteins for detecting intracellular or intravesicular biomolecular interactions |
AU2021219233A1 (en) * | 2020-02-14 | 2022-10-06 | Beijing Yongtai Ruike Biotechnology Company Ltd | Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof |
CN116490518A (zh) * | 2020-07-17 | 2023-07-25 | 西穆尔克斯股份有限公司 | 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法 |
GB202012181D0 (en) * | 2020-08-05 | 2020-09-16 | Autolus Ltd | Chimeric receptor |
WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
CN112194728B (zh) * | 2020-09-22 | 2023-07-11 | 沣潮医药科技(上海)有限公司 | 用于内毒素清除的嵌合抗原受体及其应用 |
WO2022087453A1 (en) * | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
AU2022259323A1 (en) * | 2021-04-15 | 2023-10-19 | Legend Biotech Ireland Limited | Fusion proteins and uses thereof |
WO2023288281A2 (en) * | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
CN113698493B (zh) * | 2021-08-09 | 2022-05-31 | 北京东方百泰生物科技股份有限公司 | 一种针对VEGF和TGF-β的双功能蛋白及其应用 |
EP4392463A1 (en) * | 2021-08-18 | 2024-07-03 | Legend Biotech Ireland Limited | Modified immune cells expressing tlr receptors |
WO2023030408A1 (zh) * | 2021-09-02 | 2023-03-09 | 广东菲鹏制药股份有限公司 | TGFβRII突变体及其应用 |
CN115873802A (zh) * | 2021-09-29 | 2023-03-31 | 亘喜生物科技(上海)有限公司 | 嵌合抗原受体免疫细胞及其制法和应用 |
GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
CN114539429B (zh) * | 2022-03-24 | 2022-07-29 | 上海普铭生物科技有限公司 | 融合蛋白组合物及其应用 |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
CA2093664C (en) | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1999006583A1 (en) | 1997-07-31 | 1999-02-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
CA2410828C (en) | 2000-06-01 | 2012-01-24 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
AU2002257420A1 (en) | 2001-05-01 | 2002-11-11 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
NZ555830A (en) | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
EP1783228A1 (en) * | 2005-11-08 | 2007-05-09 | ETH Zürich | Recombinant expression of multiprotein complexes using polygenes |
EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
EP2524037B1 (en) | 2010-01-12 | 2018-05-16 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
US9169492B2 (en) | 2010-02-05 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
AU2011274423B2 (en) * | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
NZ723731A (en) | 2011-04-08 | 2020-05-29 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
US10584158B2 (en) * | 2013-04-17 | 2020-03-10 | Baylor College Of Medicine | Immunosuppressive TGF-β signal converter |
WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
JP6352215B2 (ja) | 2014-07-10 | 2018-07-04 | 株式会社デンソー | ガスセンサ素子 |
WO2016122738A1 (en) * | 2015-01-31 | 2016-08-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
BR112017021510A2 (pt) * | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
CN117720665A (zh) | 2016-11-17 | 2024-03-19 | 2赛文缇生物公司 | TGFβ信号转换器 |
-
2017
- 2017-11-17 CN CN202311619803.0A patent/CN117720665A/zh active Pending
- 2017-11-17 BR BR112019009904A patent/BR112019009904A2/pt unknown
- 2017-11-17 DK DK17872043.9T patent/DK3541833T3/da active
- 2017-11-17 EP EP17872043.9A patent/EP3541833B1/en active Active
- 2017-11-17 KR KR1020247010309A patent/KR20240046620A/ko active Search and Examination
- 2017-11-17 US US16/348,450 patent/US11654158B2/en active Active
- 2017-11-17 MX MX2019005724A patent/MX2019005724A/es unknown
- 2017-11-17 MA MA046862A patent/MA46862A/fr unknown
- 2017-11-17 EP EP23216595.1A patent/EP4353822A3/en active Pending
- 2017-11-17 CN CN201780077533.1A patent/CN110072885B/zh active Active
- 2017-11-17 IL IL266628A patent/IL266628B2/en unknown
- 2017-11-17 WO PCT/US2017/062358 patent/WO2018094244A1/en unknown
- 2017-11-17 JP JP2019526305A patent/JP7263235B2/ja active Active
- 2017-11-17 CA CA3043888A patent/CA3043888A1/en active Pending
- 2017-11-17 IL IL309526A patent/IL309526A/en unknown
- 2017-11-17 AU AU2017362484A patent/AU2017362484B2/en active Active
- 2017-11-17 KR KR1020197017172A patent/KR102653324B1/ko active IP Right Grant
-
2022
- 2022-03-15 AU AU2022201775A patent/AU2022201775B2/en active Active
-
2023
- 2023-04-07 US US18/297,491 patent/US20230364141A1/en active Pending
- 2023-04-12 JP JP2023064901A patent/JP2023089135A/ja active Pending
-
2024
- 2024-05-29 AU AU2024203604A patent/AU2024203604A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7263235B2 (ja) | 2023-04-24 |
CA3043888A1 (en) | 2018-05-24 |
US11654158B2 (en) | 2023-05-23 |
EP3541833B1 (en) | 2024-01-24 |
KR20190077562A (ko) | 2019-07-03 |
IL266628B1 (en) | 2024-02-01 |
AU2017362484A1 (en) | 2019-05-30 |
IL266628B2 (en) | 2024-06-01 |
CN117720665A (zh) | 2024-03-19 |
AU2017362484B2 (en) | 2021-12-16 |
KR20240046620A (ko) | 2024-04-09 |
AU2024203604A1 (en) | 2024-06-20 |
US20190350974A1 (en) | 2019-11-21 |
AU2022201775B2 (en) | 2024-02-29 |
IL309526A (en) | 2024-02-01 |
AU2022201775A1 (en) | 2022-04-07 |
WO2018094244A1 (en) | 2018-05-24 |
EP4353822A3 (en) | 2024-07-03 |
US20230364141A1 (en) | 2023-11-16 |
JP2023089135A (ja) | 2023-06-27 |
CN110072885A (zh) | 2019-07-30 |
CN110072885B (zh) | 2023-12-19 |
IL266628A (en) | 2019-07-31 |
MA46862A (fr) | 2019-09-25 |
EP4353822A2 (en) | 2024-04-17 |
MX2019005724A (es) | 2019-07-08 |
EP3541833A4 (en) | 2020-04-29 |
BR112019009904A2 (pt) | 2019-08-13 |
KR102653324B1 (ko) | 2024-04-01 |
JP2019535275A (ja) | 2019-12-12 |
EP3541833A1 (en) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3541833T3 (da) | TGFß signalkonverter | |
DK3405050T3 (da) | Børnesikret snusbeholder | |
DK3298718T3 (da) | Teknikker til signal-forlængelsessignalering | |
DK3436823T3 (da) | Antigen-array | |
DK3335532T3 (da) | Tandharve | |
DK3445708T3 (da) | Stigbøjle | |
DK3460891T3 (da) | Termoelektrokemisk omformer | |
DK3402792T3 (da) | Quinolin-2-on-derivater | |
DK3509963T3 (da) | Pallecontainer | |
DK3438103T3 (da) | Griseofulvinforbindelse | |
DK3528829T3 (da) | Bacitracin-alginat-oligomer-konjugater | |
DK3575238T3 (da) | Pallecontainer | |
DE112017006386A5 (de) | Schraubarbeitszylinder | |
DE112017000734A5 (de) | Glycolsensor | |
DK3323708T3 (da) | Bovfender | |
DK3452590T3 (da) | Plademagnet | |
DK3471535T3 (da) | Dyrelift | |
DK3452587T3 (da) | Penicillin-g-acylaser | |
DK3430609T3 (da) | Smartflag | |
DK3295800T3 (da) | Sandwichkiksindretning | |
DE112017006474A5 (de) | Gargerätevorrichtung | |
DK3551954T3 (da) | Rekuperator | |
DE112017005767A5 (de) | Nasslaufende lamellenkupplung | |
DK3468607T3 (da) | Resveratrolsolubilisat | |
DE112017000296A5 (de) | Radgeschwindigkeitssensorvorrichtung |